Navigation Links
Mayo Clinic: Preclinical tests may lead to new approach to treat CNS lymphoma
Date:8/12/2013

JACKSONVILLE, Fla. -- A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, and eyes. The clinical trial, now open at the three campuses of Mayo Clinic -- in Florida, Minnesota and Arizona -- follows successful testing of the drug, pomalidomide, in mouse models of CNS lymphoma. Details of the preclinical testing are available in the science journal PLOS ONE.

Approximately 5,000 patients are diagnosed with the disease every year in the United States.

"We believe pomalidomide could be beneficial in patients with this cancer because it does two things that most anti-cancer drugs do not do," says Han Tun, M.D., an oncologist at Mayo Clinic in Florida. "The drug has excellent brain penetration, which is a requirement in treatment of brain tumors. The other interesting thing is that it is not only active directly against lymphoma cells but also alters the tumor microenvironment."

Dr. Tun is the senior investigator of the PLOS ONE study and the principal investigator for the clinical trial, which is accruing patients.

"Our preclinical study suggests pomalidomide is very promising. Treatment with pomalidomide in mouse models for CNS lymphoma significantly improved the survival and suppressed the tumor growth," he says. "The phase I clinical trial was developed based on these preclinical results."

Pomalidomide belongs to a class of drugs called immunomodulatory agents. Thalidomide was the first drug in this class and was approved in 2006 for treatment of multiple myeloma, a bone marrow cancer. Pomalidomide was approved for use in multiple myeloma in February.


'/>"/>

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Mayo Clinic: Obesity epidemic fueling rise in rheumatoid arthritis among women
2. Mayo Clinic: Exhaustion renders immune cells less effective in cancer treatment
3. Mayo Clinic: Standard heart disease risk tools underrate danger in rheumatoid arthritis
4. Mayo Clinic: Molecule thought cancer foe actually helps thyroid tumors grow
5. Mayo Clinic: Common blood pressure drug linked to severe GI problems
6. Mayo Clinic: Drug duo turns on cancer-fighting gene in kidney, breast cancers
7. Mayo Clinic: Diabetes can be controlled in patients after pancreas removal
8. Mayo Clinic: Antidepressant eases radiation-related mouth pain in head, neck cancer
9. Mayo Clinic: Less invasive surgery detects residual breast cancer in lymph nodes after chemotherapy
10. Mayo Clinic: 2-drug combination may slow deadly thyroid cancer
11. Mayo Clinic: Skin problems, joint disorders top list of reasons people visit doctors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... Shark Finds ... the launch of a new DRTV campaign with Belly Bands. , Having a dog ... from sprays to puppy pads and find nothing works, get Belly Bands, the ...
(Date:2/5/2016)... Toronto, Ontario (PRWEB) , ... February 05, 2016 ... ... today announced the availability of the company's lighter, sleeker next generation LYNX VR ... assembly plant. , Improvements in design and manufacturing not only reduce the ...
(Date:2/5/2016)... ... 05, 2016 , ... The Muscular Dystrophy Association and Sailormen ... the 14th annual “Appetite for a Cure” campaign on Feb. 1 to raise ... related diseases that severely limit strength and mobility. , Now through March ...
(Date:2/5/2016)... ... 05, 2016 , ... After years as an active staff surgeon and having ... surgeon Dr. Wayne Carman transitioned to chief of the Division of Plastic Surgery at ... term as chief and began a second three-year term in January of 2016. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends to ... may be safer than regular municipal or well water. The recent experience with lead ... Kleyne, could go a long way toward increasing public acceptance of recycled waste water ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... Feb. 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... biofiltration devices to treat life-threatening diseases, today announced ... ended December 31, 2015. --> ... set forth in our last quarterly call, we ... our long-term objective to establish the Aethlon Hemopurifier® ...
(Date:2/4/2016)...  Blueprint Medicines Corporation (NASDAQ: BPMC ), ... investigational kinase medicines for patients with genomically defined ... of directors of Lonnel Coats , a ... industry-related experience. Jeffrey Albers , ... strategic experience developing and commercializing numerous oncology products ...
Breaking Medicine Technology: